Standardizing Care to Manage Bleeding Disorders in Adolescents with Heavy Menses-A Joint Project from the ISTH Pediatric/Neonatal and Women's Health SSCs

Authors: Zia, A, Kouides, P, Khodyakov, D, Dao, E, Lavin, M, Kadir, RA, Othman, M, Bauman, D, Halimeh, S, Winikoff, R, and Revel-Vilk, S.

Publication: J Thromb Haemost.; June 2020

Affiliations: The University of Texas Southwestern Medical Center, Dallas, United States Division of Pediatric Hematology/Oncology, Jerusalem, Israel: The University of Rochester and the Mary M. Gooley Hemophilia Treatment Center, Rochester, NY, USA; RAND Corporation, Santa Monica, CA, United States; Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland Beaumont Hospital, Dublin, Ireland; The Royal Free Foundation Hospital and Institute for Women’s Health, University College, London, UK; Department of Biomedical and Molecular Sciences, Queen’s University Kingston, School of Baccalaureate Nursing, St Lawrence College Kingston, Kingston, Canada; Department of Pediatric and Adolescent Gynecology, Hadassah University Medical Center, Jerusalem, Israel; Medical Thrombosis and Haemophilia Treatment Center, Duisburg, Germany; Division of Hematology-Oncology, Justine University Health Center, Sainte, Montréal, Canada; Pediatric Hematology/Oncology Unit, Shaare Zedek Medical Center, Hebrew University Medical School, Jerusalem, Israel.

Abstract: BACKGROUND: Bleeding disorders (BD) are under-recognized in adolescents with heavy menstrual bleeding (HMB). OBJECTIVES: The lack of clinical guidelines and variable symptomatic management of HMB created the imperative to standardize HMB care to identify and manage BD in adolescents. METHODS: We convened an international working group (WG), utilized the results of a literature review to define knowledge gaps in HMB care, and used the collective clinical experience of the WG to develop care considerations for adolescents with BD and HMB. We then solicited input on the appropriateness of HMB care considerations from expert stakeholders representing hematology, adolescent medicine, and obstetrics-gynecology. We conducted an expert panel online, using the ExpertLens platform. During a 3-round online modified-Delphi process, the expert panel rated the appropriateness of 21 care considerations using a 9-point scale to designate care as appropriate (7-9), uncertain (4-6), or inappropriate (1-3) covering screening for BD, the laboratory work-up, and management of adolescents with BD that present with HMB. We used the RAND/UCLA appropriateness method to determine the existence of consensus among the interdisciplinary panel of experts. RESULTS: Thirty-nine experts participated in the panel. The experts rated fifteen HMB care considerations as appropriate, six as uncertain, and none as inappropriate. CONCLUSIONS: The HMB care statements represent the first set of HMB care considerations in adolescents with BD, developed with broad expert input on appropriateness. Although likely to be of interest to a range of clinicians who routinely manage adolescents with HMB, additional research is required in many key areas.